Assessment of the Protective Effects of Amifostine against Cisplatin-Induced Toxicity

Journal of Otolaryngology

Volumn 32, Issue 5, 2003, Pages 294-297

  Hussain, Abdulmohsen E ^a   Blakley, Brian W ^a   Nicolas, Marta ^b   Balderston, Janet ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF BARCELONA   (Spain)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Amifostine; Chemotherapy; Cisplatin; Hair cell; Hearing loss

Indexed keywords

AMIFOSTINE; CISPLATIN; CREATININE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDITORY BRAINSTEM RESPONSE; BONE MARROW TOXICITY; BRAIN STEM RESPONSE; CLICK; CLINICAL PROTOCOL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG TOXICITY; GUINEA PIG; HAIR CELL; HEARING LOSS; LATENT PERIOD; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; UREA BLOOD LEVEL;

EID: 0842284222     PISSN: 03816605     EISSN: None     Source Type: Journal    
DOI: 10.2310/7070.2003.11264     Document Type: Article

References (15)

1. Kurbacher CM, Mallmann PK. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721). Anticancer Res 1998; 18:2203-2210.
2. Grdina DJ, Kataoka Y, Murley JS. Amifostine mechanisms of action underlying cytoprotection and chemoprevention. Drug Metab Drug Interact 2000; 16:237-279.
3. Culy CR, Spencer CM. Amifostine an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 2001; 61:641-684.
4. Lindegaard JC, Grau C. Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol 2000; 57:113-118.
5. Capizzi RL, Oster W. Chemoprotective and radioprotective effects of amifostine: an update on clinical trials. Int J Hematol 2000; 72:425-435.
6. Wozniak K, Walter Z. Induction of DNA-protein cross-links by platinum compounds. Z Naturforsch [C] 2000; 55:731-736.
7. Peddie CM, Wolf DR, McLellan LI, et al. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumor necrosis factor-alpha concentration. Br J Haematol 1997; 99:625-631.
8. Gordon G, Vokes E. The role of chemotherapy in head and neck cancer. In: Pensak M, ed. Controversies in otolaryngology. New York: Thieme, 2001.
9. Villaret DB, Weymuller EA. The role of chemotherapy in head and neck cancer. In: Pensak ML, ed. Controversies in otolaryngology. New York: Thieme, 2001:39-48.
10. Neuwelt EA, Glasberg M, Frenkel E, Barnett P. Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathological studies. Ann Neurol 1983; 14:316-324.
11. Aviles A, Diaz-Maqueo JC, Talavera A, et al. Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma. Eur J Cancer 1997; 33:1323-1325.
12. Fichtner I, Lemm M, Becker M, Berthold F. Effects of amifostine (WR-2721, Ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas. Anticancer Drugs 1997; 8:174-181.
13. Neuwelt EA, Goldman DL, Dahlborg SA, et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991; 9:1580-1590.
14. Culy CR, Spencer CM. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer, receiving chemotherapy or radiotherapy, and its potential therapeutic application in myelodysplastic syndrome. Drugs 2001; 61:641-684.
15. Tannehill SP, Mehta MP, Larson M, et al. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial. J Clin Oncol 1997; 15:2850-2857.